Krystal Biotech Inc (KRYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.05B
Last updated: Nov 17, 2026 at 11:06 AM ET
Krystal Biotech Inc (KRYS) Stock Forecast
Analysts expect Krystal Biotech (KRYS) to earn $8.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $497.46M. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $9.23.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 8.3% |
| Buy | 10 | 83.3% |
| Hold | 1 | 8.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 15.2% and revenue estimates rise 27.6%.
- Fiscal year ending Dec 31, 2026
- $8.01
- EPS consensus, revenue $497.46M
- Fiscal year ending Dec 31, 2027
- $9.23
- EPS consensus, revenue $634.85M
- Next report
- Feb 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.01 | $7.46 to $10.48 | 9 | $497.46M | $494.00M to $500.20M | 9 |
| Dec 31, 2027 | $9.23 | $7.16 to $11.97 | 11 | $634.85M | $595.30M to $680.80M | 10 |
Quarterly Estimates
The EPS consensus falls from $2.09 for the quarter ending Dec 31, 2026 to $2.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.09 | $1.75 to $2.54 | 14 | $137.50M | $128.46M to $144.10M | 13 |
| Mar 31, 2027 | $2.08 | $1.80 to $2.52 | 4 | $139.42M | $134.40M to $144.10M | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 1 | 4 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 3.0% from $7.78.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $8.01 | $7.59 | $7.87 | $7.87 | $7.78 | +2.9% |
| Fiscal year ending Dec 31, 2027 | $9.23 | $8.95 | $9.32 | $9.40 | $9.32 | -1.0% |
| Quarter ending Mar 31, 2027 | $2.08 | $2.16 | $2.23 | $2.23 | $2.23 | -6.6% |
Frequently Asked Questions About KRYS
What is the KRYS stock forecast?
Consensus analyst estimates put Krystal Biotech's EPS at $8.01 for the fiscal year ending Dec 31, 2026, on revenue of $497.46M. The consensus rating from 12 analysts is Buy.
How do analysts rate KRYS stock?
Of 12 analysts covering Krystal Biotech, 1 rates it Strong Buy, 10 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KRYS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.01, with estimates from $7.46 to $10.48 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.23, with estimates from $7.16 to $11.97 from 11 analysts.
What revenue do analysts expect from Krystal Biotech next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $497.46M, with estimates from $494.00M to $500.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $634.85M, with estimates from $595.30M to $680.80M.
How many analysts cover KRYS?
12 analysts rate Krystal Biotech stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KRYS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors